Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, open-label, phase II, safety and efficacy study of Panzem nanocrystal colloidal dispersion [2-methoxyestradiol] administered orally in combination with protracted oral fixed-dose temozolomide to patients with recurrent glioblastoma multiforme

Next Previous
X
Search
Trial Profile

A single-center, open-label, phase II, safety and efficacy study of Panzem nanocrystal colloidal dispersion [2-methoxyestradiol] administered orally in combination with protracted oral fixed-dose temozolomide to patients with recurrent glioblastoma multiforme

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2-methoxyestradiol (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals; EntreMed

    • Most Recent Events

    • 24 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual completion date was October 2008.
    • 09 Jul 2008 Actual initiation date added form Clinicaltrials.gov.
    • 09 Jul 2008 Actual patient number (15) added from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top